Subtype
Head and Neck Undifferentiated Carcinoma
CI-CAN-00002838Explore in graph →
26 active trials2 approved drugs5 evidence items
- NCIt
- C215427
Loading cancer entity…
Subtype
CI-CAN-00002838Explore in graph →
Clinical trials
67 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (14)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06814496 | Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing Tumors(RABBIT) | recruiting | Phase 1 / Phase 2 | 30 | University of ArizonaOTHER | 1 | Sep 22, 2026 | clinicaltrials |
| NCT06176989 | Enasidenib in IDH2-Mutated Malignant Sinonasal and Skull Base Tumors | recruiting | Phase 2 | 40 | National Cancer Institute (NCI)NIH | 1 | Sep 21, 2026 | clinicaltrials |
| NCT06235216 | Sacituzumab govitEcan in THYroid Cancers(SETHY) | recruiting | Phase 2 | 42 | Grupo Espanol de Tumores NeuroendocrinosOTHER | 1 | Sep 16, 2026 | clinicaltrials |
| NCT06902376 | XL092 and Cemiplimab in BRAF WT Thyroid Cancer(NEO-COMBATXL) | recruiting | Phase 1 | 12 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Sep 8, 2026 | clinicaltrials |
| NCT06940180 | Toripalimab With Chemotherapy for Sinus Cancer | recruiting | Phase 2 | 20 | Dana-Farber Cancer InstituteOTHER | 1 | Aug 31, 2026 | clinicaltrials |
| NCT07440290 | DETERMINE Trial Treatment Arm 07: Dabrafenib in Combination With Trametinib in Adult, Paediatric and Teenage/Young Adult Patients With BRAF V600 Mutation-Positive Cancers.(DETERMINE) | recruiting | Phase 2 / Phase 3 | 30 | Cancer Research UKOTHER | 1 | Aug 17, 2026 | clinicaltrials |
| NCT07068542 | Sacituzumab Tirumotecan Combined With Immunotherapy in Advanced Thyroid Cancer | recruiting | N/A | 94 | Zhejiang Provincial People's HospitalOTHER | 1 | Jun 1, 2026 | clinicaltrials |
| NCT05925491 | Pembrolizumab in Locally Advanced Sinonasal Carcinoma(NeoPeSino) | recruiting | Phase 2 | 28 | Istituti Clinici Scientifici Maugeri SpAOTHER | 1 | Apr 16, 2026 | clinicaltrials |
| NCT03975231 | Dabrafenib, Trametinib, and IMRT in Treating Patients With BRAF Mutated Anaplastic Thyroid Cancer | recruiting | Phase 1 | 6 | City of Hope Medical CenterOTHER | 1 | Apr 8, 2026 | clinicaltrials |
| NCT06639191 | [177Lu]Lu-AKIR001 First-in-human Study(AKIR001) | recruiting | Early Phase 1 | 15 | Karolinska University HospitalOTHER | 1 | Jan 30, 2026 | clinicaltrials |
| NCT05768178 | DETERMINE Trial Treatment Arm 05: Vemurafenib in Combination With Cobimetinib in Adult Patients With BRAF Positive Cancers.(DETERMINE) | recruiting | Phase 2 / Phase 3 | 30 | Cancer Research UKOTHER | 1 | Nov 24, 2025 | clinicaltrials |
| NCT06374602 | Efficacy of Pembrolizumab and Lenvatinib in Patients With Anaplastic Thyroid Cancer | recruiting | Phase 2 | 20 | Saint Petersburg State University, RussiaOTHER | 1 | Sep 5, 2025 | clinicaltrials |
| NCT06079333 | NEO- and Adjuvant Targeted Therapy in Braf-mutated Anaplastic Cancer of the Thyroid (NEO-ATACT Study)(NEO-ATACT) | recruiting | Phase 2 | 20 | Leiden University Medical CenterOTHER | 1 | Oct 12, 2023 | clinicaltrials |
Data updated 5 days agoSource updated Sep 22, 2026source: clinicaltrials